PUBLICATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the NASH-HCC field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Publications
2000 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
No.6
PLoS One,
“Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors” (PLoS One, 8:e83481, 2013)
VIEW ARTICLE 
No.5
International Journal of Oncology,
“Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide” (Int J Oncol, 42:831-838, 2013)
VIEW ARTICLE
No.4
International Journal of Experimental Pathology,
“Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice” (Int J Exp Pathol, 94: 217-225, 2013)
VIEW ARTICLE
No.3
Medical Molecular Morphology,
“A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma” (Med Mol Morph, 46:141-152, 2013)
VIEW ARTICLE